Last week, IDL Diagnostics participated in Urology Week 2026 in Växjö. The event brought together professionals from across the field of urology and offered a valuable opportunity to engage in discussions about current research, clinical perspectives and ongoing...
Held from 7-11 September in conjunction with the visit of HRH Crown Princess Victoria of Sweden to Indonesia, Sweden-Indonesia Sustainable Partnership (SISP) Indonesia 2026 brought together more than 50 Swedish companies and Team Sweden organisations to strengthen...
Last Monday, IDL Diagnostics had the honor of attending the diplomatic reception hosted by the Embassy of the Republic of Indonesia to commemorate 81 years of Indonesia's Independence and 76 years of Indonesia–Sweden diplomatic relations. The afternoon brought...
On April 14, IDL participated at Redeye Healthcare Day. CEO Anders Hultman presented the company and shared more about its strategy, current and future markets, and our joint venture with concile. Watch the presentation here
During CACLP in Xiamen, China’s largest IVD exhibition, IDL Diagnostics had the opportunity to meet a wide range of industry players, exchange valuable insights, and further explore the fast-evolving Chinese IVD market. The trip concluded in Tianjin with our first...
Anders Hultman, Gustav Sten, Xia Jiang and Marie Torstensson have been in Shanghai, China, to meet our partners within CLIA. Currently, we have one product on the market, TPS CLIA, as well as two products in development: TK1 CLIA and UBC CLIA. The purpose of the...
IDL Diagnostics attended the European Association of Urology (EAU) 2026 conference in London last week. We had valuable discussions with physicians who use our diagnostic biomarkers in clinical practice and research. A big thank you to everyone we met at EAU26! We...
Last week, IDL Diagnostics participated as an exhibitor at WHX Labs Dubai together with concile as part of the recently announced joint venture. The main focus is on delivering multiple biomarkers across different POC reader configurations and supporting infection,...
We will be co-exhibiting together with our partner concile at Booth SA.A55. Come by our booth and learn more about our products and how quantitative point-of-care testing can be used to provide accurate and rapid results.
On January 21st Redeye hosted a Fight Cancer 2026 theme event where CEO Anders Hultman presented about the company, market opportunities and the new strategic priority. See the presentation here
